Truist Securities maintains Tenet Healthcare at Buy, raises price target to $305 from $290
Truist Securities reaffirmed its Buy rating for Tenet Healthcare and increased its price target to $305, up from $290. This target suggests a 13.4% upside from the stock's Nov 2 close. Other recent analyst price targets for Tenet range from $300 to $342.
How this was made

The 30-second read
Why it matters
A higher target can influence short-term positioning and sentiment, but without new company-specific disclosures it is unlikely to be a primary driver of fundamentals.
Market read
Valuation expectations for Tenet Healthcare get a modest upward adjustment via an analyst price-target increase.
What to watch
Traders may discount the update if Tenet’s fundamentals or guidance have not changed, and if the broader analyst dispersion (e.g., targets up to $342) already reflects a wide range of outcomes.
Background
The piece is an analyst-coverage update: Truist reiterates a Buy rating on Tenet Healthcare and increases its price target.
Ticker impact
Truist Securities maintained Tenet Healthcare at Buy and raised its price target to $305 from $290, implying upside versus the Nov 2 close.
Mild upward bias as traders price in the higher target, with follow-through depending on whether other analysts adjust similarly.
The article provides a specific, time-stamped PT change and reiterates the Buy rating, but it does not include new operational or financial disclosures from Tenet itself.
Market effects
Limited read-through to the broader healthcare services sector because the catalyst is a single-bank target change, not sector-wide guidance or regulation.
Minimal, as the news is US-focused and tied to one issuer’s analyst coverage.
Low, since it does not involve cross-border policy, supply chains, or global capital markets.
Counterpoint
The move may have limited impact if the market already expects similar valuation support, making the PT change more incremental than directional.
Key entities
- companyTenet Healthcare
Subject of the analyst action, with a Buy rating maintained and price target raised to $305 from $290.
- analyst_firmTruist Securities
The brokerage issuing the maintained rating and updated price target.


